164 related articles for article (PubMed ID: 31549211)
1. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
[TBL] [Abstract][Full Text] [Related]
2. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
[TBL] [Abstract][Full Text] [Related]
3. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Contrast-Enhanced MRI-Upgraded Prostate Imaging Reporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.
Abreu-Gomez J; Krishna S; Narayanasamy S; Flood TA; McInnes MDF; Schieda N
AJR Am J Roentgenol; 2019 Oct; 213(4):836-843. PubMed ID: 31120786
[No Abstract] [Full Text] [Related]
5. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
[TBL] [Abstract][Full Text] [Related]
7. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.
Vos EK; Litjens GJ; Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Huisman HJ; Scheenen TW
Eur Urol; 2013 Sep; 64(3):448-55. PubMed ID: 23751135
[TBL] [Abstract][Full Text] [Related]
8. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer.
Alessandrino F; Taghipour M; Hassanzadeh E; Ziaei A; Vangel M; Fedorov A; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Jan; 44(1):279-285. PubMed ID: 30066169
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of dynamic
Tau N; Berlin A; Yeung I; Halankar J; Murphy G; Jhaveri KS; Ghai S; Metser U
Br J Radiol; 2019 Feb; 92(1094):20180568. PubMed ID: 30383459
[TBL] [Abstract][Full Text] [Related]
11. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
[TBL] [Abstract][Full Text] [Related]
12. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
Asvadi NH; Afshari Mirak S; Mohammadian Bajgiran A; Khoshnoodi P; Wibulpolprasert P; Margolis D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2018 Nov; 43(11):3117-3124. PubMed ID: 29725743
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference.
Mohammadian Bajgiran A; Afshari Mirak S; Shakeri S; Felker ER; Ponzini D; Ahuja P; Sisk AE; Lu DS; Raman SS
Abdom Radiol (NY); 2019 Mar; 44(3):1052-1061. PubMed ID: 30460528
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers.
Abreu-Gomez J; Lim C; Cron GO; Krishna S; Sadoughi N; Schieda N
Abdom Radiol (NY); 2021 Sep; 46(9):4370-4380. PubMed ID: 33818626
[TBL] [Abstract][Full Text] [Related]
16. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
17. High spatiotemporal resolution dynamic contrast-enhanced MRI improves the image-based discrimination of histopathology risk groups of peripheral zone prostate cancer: a supervised machine learning approach.
Winkel DJ; Breit HC; Block TK; Boll DT; Heye TJ
Eur Radiol; 2020 Sep; 30(9):4828-4837. PubMed ID: 32328763
[TBL] [Abstract][Full Text] [Related]
18. Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion.
Shin N; Park SY
AJR Am J Roentgenol; 2020 Oct; 215(4):913-919. PubMed ID: 32755167
[No Abstract] [Full Text] [Related]
19. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
[TBL] [Abstract][Full Text] [Related]
20. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
